Viability of selected microorganisms in parenteral preparations for novel systemic anti-cancer therapy
Journal of Oncology Pharmacy Practice · 2024
DOI: 10.1177/10781552231179185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology Pharmacy Practice, 2024. Verfasst von Jannik Almasi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University Medical Center, Johannes Gutenberg-University, Mainz, Germany. Hauptthemen laut MEDLINE: Candida albicans, Pseudomonas aeruginosa, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Risk factors for aseptic preparation of parenteral medicines encompass the growth-promoting nature of the preparation. Although many aqueous parenteral preparations do not have growth-promoting properties, inadvertently introduced microorganisms may remain viable. Knowledge about the viability of microorganisms in parenteral preparations can add useful information for assigning shelf life to preparations used to treat cancer patients.
Aim
The aim of the study was to assess the viability of four different facultative pathogenic microorganisms in 20 ready-to-administer parenteral preparations aseptically prepared in hospital pharmacies.
Methods
Samples of 20 different biologics and small molecules for systemic anti-cancer therapy were inoculated either with different bacteria (i.e., Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus faecium) or with Candida albicans suspension. The resulting test concentrations were 10 4 –10 5 microorganisms per mL. Aliquots of inoculated test solutions were transferred in duplicate to tryptic soy agar plates at the time points 0, 4, 24, 48, 144 h. The plates were incubated for 24 h (bacterial strains) and 72 h ( C. albicans) at 37 °C and colony forming units (CFUs) were counted.
Results
In most test solutions, especially in monoclonal antibody solutions, increased CFU counts of P. aeruginosa and unchanged or increased CFU counts of E. faecium and S. aureus were registered . Pronounced nutritive properties of monoclonal antibodies and filgrastim were not registered. Azacitidine, pixantrone and vinflunine containing test solutions revealed species-specific bacteriostatic and even bactericidal activity. All test solutions, except nivolumab and pixantrone containing solutions, showed constant or increasing CFU counts of C. albicans after incubation.
Conclusion
Viability of the selected pathogenic microorganisms was retained in most of the tested biological and small molecule preparations used to treat cancer patients. Therefore, in pharmacy departments strict aseptic conditions should be regarded and the lack of antimicrobial activity should be considered when assigning shelf life to RTA parenteral preparations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
ORCID-Profile: Jannik Almasi, Irene Krämer
Zitieren
APA
Almasi, J., Knoll, L., Thiesen, J., & Krämer, I. (2024). Viability of selected microorganisms in parenteral preparations for novel systemic anti-cancer therapy. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552231179185
Vancouver
Almasi J, Knoll L, Thiesen J, Krämer I. Viability of selected microorganisms in parenteral preparations for novel systemic anti-cancer therapy. Journal of Oncology Pharmacy Practice. 2024. doi:10.1177/10781552231179185
BibTeX
@article{Almasi2024,
author = {Almasi, Jannik and Knoll, Laura and Thiesen, Judith and Krämer, Irene},
title = {Viability of selected microorganisms in parenteral preparations for novel systemic anti-cancer therapy},
journal = {Journal of Oncology Pharmacy Practice},
year = {2024},
doi = {10.1177/10781552231179185}
}
EUVIMED